Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 11/20 | 0.70 |
| ▸ | GRM1 | Q13255 | 11/20 | 0.70 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.57 |
| ▸ | NAMPT | P43490 | 1/20 | 0.53 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.51 |
| ▸ | HTR6 | P50406 | 1/20 | 0.50 |
| ▸ | WNT3A | P56704 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29559340 | 1.00 | GRM5 (0.70) | GRM5GRM1PDK4NAMPTPDE10A | |
| SCHEMBL17722891 | 0.89 | GRM5 (0.58) | GRM5GRM1PDK4 | |
| SCHEMBL31334406 | 0.88 | GRM5 (0.55) | GRM5GRM1PDK4NAMPTPDE10A | |
| SCHEMBL30308912 | 0.86 | GRM1 (0.64) | GRM5GRM1PDK4NAMPTPDE10A | |
| SCHEMBL15024195 | 0.85 | GRM1 (0.60) | GRM5GRM1PDK4NAMPTWNT3A | |
| SCHEMBL7470566 | 0.85 | GRM5 (0.60) | GRM5GRM1PDK4NAMPTPDE10A | |
| SCHEMBL1199533 | 0.84 | GRM1 (0.58) | GRM5GRM1PDK4NAMPTWNT3A | |
| SCHEMBL12975531 | 0.83 | GRM1 (1.00) | GRM5GRM1PDK4NAMPTPDE10A | |
| SCHEMBL1199388 | 0.83 | NAMPT (0.59) | GRM5GRM1PDK4NAMPTPDE10A | |
| SCHEMBL25219088 | 0.82 | GRM1 (0.56) | GRM5GRM1PDK4NAMPTWNT3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102241666-A | Method for producing hydrochloride of dopamine D4 receptor agonist A-412997 | SUZHOU ITIC MEDCHEM CO LTD | 2011-11-16 | — | — | CN | claimed |
| US-10961225-B2 | Bicyclic AZA compounds as muscarinic M1 receptor and/or M4 receptor | HEPTARES THERAPEUTICS LIMITED (GB) | 2021-03-30 | — | — | US | disclosed |
| US-20200325118-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR | NXERA PHARMA UK LIMITED (GB) | 2020-10-15 | — | — | US | disclosed |
| US-10689368-B2 | Bicyclic aza compounds as muscarinic M1 receptor and/or M4 receptor | HEPTARES THERAPEUTICS LIMITED (GB) | 2020-06-23 | — | — | US | disclosed |
| US-10385039-B2 | Bicyclic aza compounds as muscarnic M1 receptor and/or M4 receptor antagonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2019-08-20 | — | — | US | disclosed |
| US-20190112294-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARNIC M1 RECEPTOR AND/OR M4 RECEPTOR ANTAGONISTS | NXERA PHARMA UK LIMITED (GB) | 2019-04-18 | — | — | US | disclosed |
| US-10233191-B2 | Fused piperidine amides as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-03-19 | — | — | US | disclosed |
| US-10233191-B2 | Fused piperidine amides as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-03-19 | — | — | US | disclosed |
| US-10196380-B2 | Bicyclic aza compounds as muscarinic M1 receptor and/or M4 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2019-02-05 | — | — | US | disclosed |
| US-20180179184-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2018-06-28 | — | — | US | disclosed |
| US-20070265249-A1 | Fused Bicyclic Aromatic Compounds that are Useful in Treating Sexual Dysfunction | ABBVIE INC. | 2007-11-15 | — | — | US | disclosed |
| US-7235661-B2 | Fused bicyclic aromatic compounds that are useful in treating sexual dysfunction | ABBOTT LABORATORIES (US) | 2007-06-26 | — | — | US | disclosed |
| US-20060172995-A1 | Fused bicyclic aromatic compounds that are useful in treating sexual dysfunction | ABBVIE INC. | 2006-08-03 | — | — | US | disclosed |
| US-7057042-B2 | Fused bicyclic aromatic compounds that are useful in treating sexual dysfunction | ABBOTT LABORATORIES (US) | 2006-06-06 | — | — | US | disclosed |
| US-20060079533-A1 | Methods of treating alzheimer's disease | NIEMAN JAMES A | 2006-04-13 | — | — | US | disclosed |
| US-20050176727-A1 | Oximes and hydrazones that are useful in treating sexual dysfunction | ABBOTT LABORATORIES | 2005-08-11 | — | — | US | disclosed |
| US-20040063713-A1 | Fused bicyclic aromatic compounds that are useful in treating sexual dysfunction | ABBVIE INC. | 2004-04-01 | — | — | US | disclosed |
| WO-2002076440-A2 | METHODS OF TREATING ALZHEIMER'S DISEASE WITH PIPERIDIN DERIVATES | ELAN PHARMACEUTICALS, INC. (US) | 2002-10-03 | — | — | WO | disclosed |
| US-6150526-A | Piperidine derivative having renin inhibiting activity | HOFFMANN-LA ROCHE INC. (US) | 2000-11-21 | — | — | US | disclosed |
| US-6051712-A | PREVENTION OF HIGH BLOOD PRESSURE AND CARDIAC INSUFFICIENCY, AS WELL AS GLAUCOMA, CARDIAC INFARCT, KIDNEY INSUFFICIENCY AND RESTENOSIS | HOFFMANN-LA ROCHE INC. (US) | 2000-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200325118-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR | CHRM1, CHRM2, CHRM4 | GRM5 124/4885GRM1 29/4885PDK4 3894/4885 |
| US-20040063713-A1 | Fused bicyclic aromatic compounds that are useful in treating sexual dysfunction | CYP19A1, CYP17A1, HSD17B11 | GRM5 902/4885GRM1 688/4885PDK4 2130/4885 |
| US-20050176727-A1 | Oximes and hydrazones that are useful in treating sexual dysfunction | CYP19A1, SHBG, CYP17A1 | GRM5 1970/4885GRM1 2041/4885PDK4 824/4885 |
| US-10233191-B2 | Fused piperidine amides as modulators of ion channels | TRPV1, TRPA1, KCNJ2 | GRM5 180/4885GRM1 207/4885PDK4 1339/4885 |
| US-10196380-B2 | Bicyclic aza compounds as muscarinic M1 receptor and/or M4 receptor agonists | CHRM1, CHRM2, CHRM4 | GRM5 120/4885GRM1 24/4885PDK4 3976/4885 |
| US-20070265249-A1 | Fused Bicyclic Aromatic Compounds that are Useful in Treating Sexual Dysfunction | CYP19A1, CYP17A1, HSD17B11 | GRM5 1753/4885GRM1 1231/4885PDK4 1781/4885 |
| US-20060172995-A1 | Fused bicyclic aromatic compounds that are useful in treating sexual dysfunction | CYP19A1, CYP17A1, DDC | GRM5 1093/4885GRM1 1843/4885PDK4 1877/4885 |
| US-20190112294-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARNIC M1 RECEPTOR AND/OR M4 RECEPTOR ANTAGONISTS | CHRM1, CHRM2, CHRM5 | GRM5 94/4885GRM1 25/4885PDK4 3948/4885 |
| US-10961225-B2 | Bicyclic AZA compounds as muscarinic M1 receptor and/or M4 receptor | CHRM1, CHRM2, CHRM4 | GRM5 124/4885GRM1 29/4885PDK4 3894/4885 |
| US-10689368-B2 | Bicyclic aza compounds as muscarinic M1 receptor and/or M4 receptor | CHRM1, CHRM2, CHRM4 | GRM5 124/4885GRM1 29/4885PDK4 3894/4885 |
| US-20060079533-A1 | Methods of treating alzheimer's disease | BACE1, PSEN1, PSEN2 | GRM5 768/4885GRM1 572/4885PDK4 3371/4885 |
| US-10385039-B2 | Bicyclic aza compounds as muscarnic M1 receptor and/or M4 receptor antagonists | CHRM1, CHRM2, CHRM5 | GRM5 94/4885GRM1 25/4885PDK4 3948/4885 |
| US-20180179184-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR AGONISTS | CHRM1, CHRM2, CHRM4 | GRM5 120/4885GRM1 24/4885PDK4 3976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.